Company intelligence / Profile preview

aaVective

Heidelberg, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

aaVective is a German biotechnology company specializing in the development of next-generation adeno-associated virus (AAV) vectors for gene therapy. Spun out from Heidelberg University, the company utilizes a proprietary platform to engineer AAV capsids with enhanced tissue specificity and reduced immunogenicity. Their technology aims to overcome current limitations in gene delivery, particularly for applications in oncology and infectious diseases. By employing directed evolution and rational design, aaVective creates customized viral vehicles tailored for precise therapeutic payloads.

Therapeutic areas: Infectious DiseasesOncology
Modalities: Gene therapyViral vector
Industry: Biotech

Beyond the preview

Go deeper on aaVective.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aaVective.

Explore the full profile